Immutep Ltd.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
GILDGilead Sciences, Inc. 3.36%75.301.0%$2155.98m
AMGNAmgen, Inc. 3.83%205.861.3%$947.68m
REGNRegeneron Pharmaceuticals, Inc. 5.44%473.992.6%$817.76m
BIIBBiogen, Inc. 7.22%318.171.5%$763.25m
MRNAModerna, Inc. 0.42%30.180.0%$642.98m
VRTXVertex Pharmaceuticals, Inc. 6.65%231.681.9%$561.91m
ILMNIllumina, Inc. 1.55%273.223.5%$490.16m
ALXNAlexion Pharmaceuticals, Inc. 3.45%86.912.0%$274.94m
AAgilent Technologies, Inc. 1.64%71.891.6%$240.38m
EXASEXACT Sciences Corp. 0.92%58.4321.0%$207.35m
INCYIncyte Corp. 3.13%71.122.5%$172.79m
SGENSeattle Genetics, Inc. 4.34%114.016.1%$169.33m
BMRNBioMarin Pharmaceutical, Inc. 3.60%82.374.3%$166.12m
NVAXNovavax, Inc. 8.89%14.21114.7%$163.28m
CODXCo-Diagnostics, Inc. -10.27%8.210.0%$133.25m

Company Profile

Immutep Ltd. is a biotechnology company, which engages in the research and development of immunotherapeutic treatments for cancer and autoimmune diseases. Its product is IMP321, which involves in clinical development for the treatment of breast cancer and melanoma. The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.